RICHARD H. SCHELLER - 16 Feb 2023 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
/s/ Brian C. Stephenson, Attorney-in-Fact
Issuer symbol
BBIO
Transactions as of
16 Feb 2023
Net transactions value
-$16,483
Form type
4
Filing time
21 Feb 2023, 19:21:54 UTC
Previous filing
18 Nov 2022
Next filing
09 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Options Exercise +3,196 +6.2% 55,126 16 Feb 2023 Direct F1
transaction BBIO Common Stock Tax liability $16,483 -1,304 -2.4% $12.64 53,822 16 Feb 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Restricted Stock Units Options Exercise $0 -3,196 -20% $0.000000 12,783 16 Feb 2023 Common Stock 3,196 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

RICHARD H. SCHELLER is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,196 shares of Common Stock underlying the Reporting Person's RSUs.
F3 The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.